Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD

26.22  -0.34 (-1.28%)

After market: 26.22 0 (0%)

Fundamental Rating

4

Taking everything into account, CGON scores 4 out of 10 in our fundamental rating. CGON was compared to 561 industry peers in the Biotechnology industry. While CGON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CGON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CGON had negative earnings in the past year.
CGON had a negative operating cash flow in the past year.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CGON has a better Return On Assets (-11.66%) than 84.67% of its industry peers.
CGON's Return On Equity of -12.00% is amongst the best of the industry. CGON outperforms 88.59% of its industry peers.
Industry RankSector Rank
ROA -11.66%
ROE -12%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has more shares outstanding than it did 1 year ago.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 56.97 indicates that CGON is not in any danger for bankruptcy at the moment.
The Altman-Z score of CGON (56.97) is better than 98.93% of its industry peers.
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 56.97
ROIC/WACCN/A
WACC10.1%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CGON has a Current Ratio of 35.30. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CGON (35.30) is better than 98.93% of its industry peers.
CGON has a Quick Ratio of 35.30. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 35.30, CGON belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 35.3
Quick Ratio 35.3
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CGON have decreased strongly by -31.90% in the last year.
CGON shows a strong growth in Revenue. In the last year, the Revenue has grown by 458.33%.
The Revenue for CGON have been decreasing by -52.09% on average. This is quite bad
EPS 1Y (TTM)-31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)458.33%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-90.17%

3.2 Future

CGON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.81% yearly.
CGON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 279.53% yearly.
EPS Next Y-29.51%
EPS Next 2Y-9.72%
EPS Next 3Y19.81%
EPS Next 5YN/A
Revenue Next Year-10.89%
Revenue Next 2Y954.83%
Revenue Next 3Y512.87%
Revenue Next 5Y279.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGON. In the last year negative earnings were reported.
Also next year CGON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as CGON's earnings are expected to grow with 19.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.72%
EPS Next 3Y19.81%

More info and screens

0

5. Dividend

5.1 Amount

CGON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (5/21/2025, 8:00:00 PM)

After market: 26.22 0 (0%)

26.22

-0.34 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)N/A N/A
Inst Owners95.99%
Inst Owner Change11.44%
Ins Owners1.54%
Ins Owner Change0%
Market Cap2.00B
Analysts81.33
Price Target63.88 (143.63%)
Short Float %17.01%
Short Ratio7.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.65%
Min EPS beat(2)-33.19%
Max EPS beat(2)19.89%
EPS beat(4)2
Avg EPS beat(4)-2.2%
Min EPS beat(4)-33.19%
Max EPS beat(4)26.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)218.27%
Min Revenue beat(2)-59.54%
Max Revenue beat(2)496.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.3%
PT rev (3m)-8.48%
EPS NQ rev (1m)-2.67%
EPS NQ rev (3m)1.02%
EPS NY rev (1m)0.25%
EPS NY rev (3m)0.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.38%
Revenue NY rev (1m)21.31%
Revenue NY rev (3m)82.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1754.6
P/FCF N/A
P/OCF N/A
P/B 2.73
P/tB 2.73
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0.01
BVpS9.62
TBVpS9.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.66%
ROE -12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 731.25%
Cap/Sales 20.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.3
Quick Ratio 35.3
Altman-Z 56.97
F-Score6
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-29.51%
EPS Next 2Y-9.72%
EPS Next 3Y19.81%
EPS Next 5YN/A
Revenue 1Y (TTM)458.33%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-90.17%
Revenue Next Year-10.89%
Revenue Next 2Y954.83%
Revenue Next 3Y512.87%
Revenue Next 5Y279.53%
EBIT growth 1Y-106.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.36%
EBIT Next 3Y28.15%
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A